News und Analysen
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older
Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for
Humana Military Names Alefiyah Mesiwala, M.D., Chief Medical Officer
Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today the appointment of Alefiyah Mesiwala, M.D., MPH, as Humana Military’s new Chief Medical Officer. Effective
Mercy and Humana Team Up to Expand Access to Virtual Health Services and Coordinated Care
Missouri-based Mercy and leading health and well-being company Humana Inc. (NYSE: HUM) have signed an agreement to expand patient access to virtual health resources as part of a broader, joint
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine
Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link
Waters Corporation (NYSE:WAT) today announced it has entered a reseller agreement with TetraScience, a cloud technology innovator powering transformational changes in life sciences R&D. Through the
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne
PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening
PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or
Quidel to Present at Upcoming Conferences
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at
Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41st Annual
PerkinElmer Provides an Update on Valencia Branch Laboratory’s Accreditation Process
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process. The
Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases
February 19, 2021 -- Illumina, Inc. (Nasdaq: ILMN) today announced an agreement with the Institute of Medical Genetics and Applied Genomics at the University Hospital of Tübingen to assess the
Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies
Agilent Technologies Inc. (NYSE: A) has earned the number two position on Barron’s annual list of America’s Most Sustainable Companies. The ranking marks the third straight year Agilent has been
Quidel Reports Fourth Quarter and Full Year 2020 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of
Dexcom Announces Upcoming Virtual Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:
-
Quentin Blackford, Chief Operating
Humana Launches Humana Care Support Pilot to Help Medicare Advantage Members to Better Manage Their Chronic Conditions
Humana Inc. (NYSE: HUM) recently launched a pilot for its new Humana Care Support, formerly known as the Enterprise Clinical Operating Model (ECOM), to help support a select group of Medicare
Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyzer for improved immune cell metabolic
Reckitt Benckiser Standardizes on Veeva Commercial Cloud Applications to Advance Digital Excellence Globally
Veeva Systems (NYSE: VEEV) today announced that RB (Reckitt Benckiser), a leading provider of consumer hygiene, health, and nutrition products, is using Veeva CRM and Veeva Vault PromoMats to
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY®, the companies’
Mehr als 250 Unternehmen transformieren regulatorische Abläufe mit Veeva Vault RIM-Anwendungen
Veeva Systems (NYSE: VEEV) gab heute bekannt, dass mehr als 250 Unternehmen Veeva Vault RIM-Anwendungen für das durchgängige Management regulatorischer Daten nutzen. Eine wachsende Zahl von
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.55 billion for the first quarter ended Jan. 31, 2021, an increase of 14% compared to the first quarter of 2020 and up 11% on a core(
PerkinElmer to Present at Cowen Health Care Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the 41st Annual Cowen Health Care Conference on